Organon & Co.
Organon & Co. (NASDAQ: OGN) is a global healthcare company dedicated to delivering impactful medicines and solutions across women's health and general medicines. The company maintains a portfolio of over 70 products distributed to patients in more than 140 countries and territories, with approximately 74% of revenues… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Organon & Co. does
In the company’s own words
Organon & Co. (NASDAQ: OGN) is a global healthcare company dedicated to delivering impactful medicines and solutions across women's health and general medicines. The company maintains a portfolio of over 70 products distributed to patients in more than 140 countries and territories, with approximately 74% of revenues generated outside the United States. Visit www.organon.com for additional information.
The company operates through two primary business segments. Women's Health, representing approximately 28% of total revenues, focuses on prescription medications in contraception and fertility treatment areas. Key brands include Nexplanon, a long-acting reversible contraceptive implant, and NuvaRing, a monthly vaginal contraceptive ring, along with fertility treatments such as Follistim AQ and Elonva. General Medicines comprises approximately 72% of revenues and includes both biosimilars and established brands. The biosimilars portfolio spans immunology and oncology-related treatments, featuring products such as Hadlima, Brenzys, Renflexis, and Tofidence, along with oncology biosimilars including Ontruzant, Aybintio, Bildyos, and Bilprevda. The established brands portfolio includes cardiovascular, respiratory, dermatology, and non-opioid pain management products, with leading brands such as Singulair, Asmanex, Fosamax, and Vtama.
Organon generated total revenues of $6.2 billion in 2025 and employs over 10,000 people worldwide, with approximately 1,500 employees in the United States and Puerto Rico. The company operates six manufacturing facilities located in Belgium, Brazil, Indonesia, Mexico, the Netherlands, and the United Kingdom, supporting its global supply chain and distribution network. Approximately 4,000 employees focus on commercialization activities including marketing, direct sales, and digital engagement.
The company was established as a spinoff from Merck & Co., Inc. in 2021 and has since pursued strategic acquisitions to expand its portfolio, including the acquisition of Dermavant Sciences in October 2024 to strengthen its dermatology offerings. Organon's business model emphasizes leveraging its scale, manufacturing capabilities, and commercial presence to deliver established and innovative pharmaceutical solutions while pursuing opportunities to collaborate with biopharmaceutical innovators.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- JERSEY CITY, NJ
- Fiscal year end
- December
- CIK
- 1821825
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Organon & Co. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Organon & Co.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Organon & Co.’s bonds, as funds hold them
Funds report holding 7 issues of Organon & Co.’s debt, $808.50M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 4.98%, maturing 2028 to 2034.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Organon & Co. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Organon & Co.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Organon & Co.'s last four quarterly filings that the numbers alone won't show?”